The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1616
January 25, 2021
View Complete Issue         Table of Contents 2019 
Encorafenib (Braftovi) for Metastatic Colorectal Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Encorafenib (Braftovi) for Metastatic Colorectal Cancer
January 25, 2021 (Issue: 1616)
The FDA has approved the oral kinase inhibitor encorafenib (Braftovi – Pfizer), in combination with the epidermal growth factor receptor (EGFR) inhibitor cetuximab (Erbitux), for treatment of adults with metastatic colorectal cancer (CRC) with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Encorafenib (Braftovi) for Metastatic Colorectal Cancer
Article code: 1616d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.